I do have a strong view that "we agreed to your trial design, then rejected your filing for the trial design" is not how a functioning regulatory process works.
The stated rationale -- wrong comparator vaccine for seniors -- is thin when you read the details. Moderna says FDA agreed to their trial design in 2024.
As recently as August, FDA indicated they'd review the filing and assess comparator issues during that process. Now it's a refusal-to-file.
I did some research and found a refusal-to-file letters hit about 4% of submissions.
For vaccines specifically, after years of sponsor-FDA dialogue, it's genuinely rare. The FDA didn't cite safety concerns. Didn't cite efficacy concerns. Just: wrong comparator.
Meanwhile Prasad's internal memo last year killed the streamlined flu approval process that's worked for decades — prompting a dozen former FDA commissioners to publicly object.
EU, Canada, and Australia accepted the same application. Not to claim they can't be wrong but...American biotech, built here, approved everywhere else first.
Doesn't feel like a win.